NCT03943602

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen)

Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC): an Open-label, Single-center, Phase 2, Single-arm Trial (CaboPen)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Cabozantinib in patients with advanced penile squamous cell carcinoma (PSCC): an open-label, single-center, phase 2, single-arm trial (CaboPen)

Detailed description

an open-label, single-center, phase 2, single-arm trial

Conditions

• Penile Squamous Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Cabozantinib	Cabozantinib 60 mg/day orally

Timeline

• Start date: 2019-08-01
• Primary completion: 2022-06-01
• Completion: 2022-09-01
• First posted: 2019-05-09
• Last updated: 2021-02-25

Locations

1 site across 1 country: Italy